Skip to main content

Work Packages

The work packages are the backbone and building blocks of EPIVINF. Check them out to understand what our objectives are and how we organise ourselves to achieve them. 

Harmonization of clinical data and cohort studies

The objective is to harmonize the patient selection and sample processing. EPIVINF works with different cohorts established in three European countries and researchers will dedicate significant efforts to ensure that clinical profiles are comparable and controlled, but also that the samples are processed following comparable protocols. This is important so that the downstream analyses and results can be properly compared.

This WP also covers tasks related to data protection, ethics committee approvals and interactions with regulatory agencies to plan future development of novel strategies for personalized medicines.

Lead partner

Epigenetic signatures in HIV and SARS-CoV-2 infection and impact on virus-specific host immunity and virus control

We aim to better understand the molecular pathways that are epigenetically disrupted due to acute HIV or SARS-CoV-2 infection and which:
a) determine the severity of HIV- and COVID19 disease course and
b) are related to the loss of immune control over co-pathogens.
 

Lead partner

Role of epigenetic regulation in the response to HIV and SARS-CoV-2 vaccination

The overall objective of WP3 is to test the hypothesis that epigenetic control mechanisms, especially DNA methylation processes that govern the expression of host proteins involved in antiviral immunity to HIV and SARS-CoV-2, play a decisive role in the outcome of vaccination for these pathogens. 

Lead partner

Epigenetic regulation of host factors involved in HIV neuro-associated disorders and long-COVID/PACS with neurological consequences

The objective of this WP is to better understand the molecular pathways that are epigenetically dysregulated due to HIV or SARS-CoV-2 infection, and which thus lead to severe and persistent neurological disease. 

Lead partner

Therapeutic targeting of epigenetically controlled antiviral host factors

The objective of WP5 is to validate epigenetic signatures observed in HIV and SARS-CoV-2 infection using in vitro experimentation and animal models. These studies will help us to advance identified lead candidates towards therapeutic use in personalized treatment strategies. 

Lead partner

Biosystems analyses in HIV and SARS-CoV-2 infection

Three main aspects are covered in this work package:

  • Central data storing, cleaning, normalization and pre-processing
  • Systems biology analysis using network-based approaches
  • Making the data and models accessible to researchers within the consortium and to other researchers in Europe and worldwide as web-based solutions

Lead partner

Management, communication and exploitation

The aim of WP7 is to ensure that 1) the overall scientific and administrative management is steered in a proper way to achieve project objectives and comply with EU Commission guidelines; 2) to implement an effective responsible research and innovation (RRI), dissemination and communication strategy that will enable stakeholders’ engagement and involvement with other consortia and 3) to put in place an exploitation plan. 

Lead partner

Ethics requirements

The objective is to ensure compliance with the ethics requirements set out in this work package. 

Lead partner

EPIVINF